Please ensure Javascript is enabled for purposes of website accessibility

Why Lexicon Is Poised to Pull Back

By Brian D. Pacampara, CFA - Apr 24, 2013 at 9:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-lagging returns could be written in this 2-Star.

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Lexicon Pharmaceuticals (LXRX 4.35%) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Lexicon and see what CAPS investors are saying about the stock right now.

Lexicon facts

Headquarters (founded)

The Woodlands, Texas (1995)

Market Cap

$1.2 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$1.1 million

Management

Co-Founder/CEO Arthur Sands
Co-Founder/Chief Technology Officer Brian Zambrowicz

Return on Equity (average, past 3 years)

(43.8%)

Cash/Debt

$222.8 million / $23.5 million

Competitors

Aptalis Pharma
Deltagen
TolerRx

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 21% of the 63 All-Star members who have rated Lexicon believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, touched on the stock's seemingly unsustainable valuation:

If there's one thing recent history has told us about Lexicon, it's that a market cap of over a billion for their highly speculative pipeline will not hold. Lexicon has assets, to be sure, and at a market cap of [$500M] or even [$600M] in this frothy market you wouldn't be hearing anything about them from me. But LX4211 doesn't have a clear place in the rapidly evolving field of glycemic control, and progression to phase III is on hold as a partnership is awaited. Telotristat is in the early stages of what undoubtedly will be a long phase III trial for the narrow indication of carcinoid. If the last year's pattern holds, the share price will be well under [$2 per share] again before any positive catalysts emerge from the pipeline.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
LXRX
$1.68 (4.35%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.